Search Results

FDA approves controversial drug for use against Alzheimer’s disease, despite evidence showing it doesn’t work

July 02, 2021 -

The drug, known as aducanumab, is the first Alzheimer's treatment approved by the FDA in almost 20 years. It will be marketed as Aduhelm. Biogen is also charging $56,000 per year for aducanumab. It is meant to be given as an infusion every four weeks.

The FDA approved the drug based on the results of studies that showed it seemed "reasonably likely" to benefit Alzheimer's patients. It is also the only therapy that regulators have said can likely treat ...

New FDA-approved “miracle” drugs ACCELERATE formation of arthritis, Alzheimer’s

January 17, 2023 - aducanumab), which recently gained approval from the U.S. Food and Drug Administration (FDA).

Aduhelm received "accelerated approval" from the FDA, which in the context of a major drug rollout is an instant red flag. This almost always means that corners were cut, or safety and efficacy standards reduced, to demonstrate its "safety and effectiveness."

"Aduhelm received 'accelerated approval' from the FDA in June despite the fact that an independent panel ...

Ancient “Mushroom of Immortality” outperforms drugs in Alzheimer’s prevention

May 20, 2025 - aducanumab.

3. Neuroinflammation neutralized

Chronic brain inflammation fuels Alzheimer’s progression. Reishi’s triterpenes shift microglia from destructive M1 (pro-inflammatory) to protective M2 (anti-inflammatory) states. Human trials show reishi spore powder lowers inflammatory markers (IL-6, TNF-?) within weeks.The emperor’s secret, now backed by science

For centuries, Chinese emperors consumed reishi to enhance longevity. Modern research validates ...

FDA approved 24 drugs in 2022 based on a SINGLE study

August 17, 2023 - aducanumab – was approved to treat Alzheimer’s. According to David Gortler, a pharmacologist and FDA reform advocate at the Ethics and Public Policy Center, the FDA expedited the drug’s approval “based on zero positive studies.”

The Act not only provided $500 million in taxpayer dollars over nine years to facilitate the corruption at the FDA, but it also provided an additional $6.3 billion to the National Institutes of Health to expedite research at American universities....

ICER: FDA failed to protect patients from unproven Alzheimer’s treatment with known harms

June 13, 2021 - aducanumab that might have helped to resolve disputes about efficacy quickly and cleanly," Howard said. "Now, we'll wait a decade before it becomes obvious to everyone that there are no benefits – only high healthcare costs – associated with the treatment."Biogen slammed over decision to price Aduhelm at $56,000 per year

Meanwhile, Biogen has been taking flak over its decision to price Aduhelm at $56,000 per year. ICER said a fair price would be in the $2,500 to $8,300 ...